Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ritchie

Showing results (651-660 of 669) with videos related to

Pageof 67
Sort By:
Nature Genetics|April 26, 2016
Punctuated bursts in human male demography inferred from 1,244 worldwide Y-chromosome sequencesG David Poznik, Yali Xue, Fernando L Mendez, et al.
Science (New York, N.Y.)|October 5, 2013
Integrative annotation of variants from 1092 humans: application to cancer genomicsEkta Khurana, Yao Fu, Vincenza Colonna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trialN W Clarke, A Ali, F C Ingleby, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
Nucleic Acids Research|November 4, 2010
Ensembl 2011Paul Flicek, M Ridwan Amode, Daniel Barrell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
Lancet (London, England)|October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialChristopher C Parker, Nicholas D James, Christopher D Brawley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003N W Clarke, A Ali, F C Ingleby, et al.
Pageof 67

Showing results (651-660 of 669) with videos related to

Sort By:
Pageof 67
Nature Genetics|April 26, 2016
Punctuated bursts in human male demography inferred from 1,244 worldwide Y-chromosome sequencesG David Poznik, Yali Xue, Fernando L Mendez, et al.
Science (New York, N.Y.)|October 5, 2013
Integrative annotation of variants from 1092 humans: application to cancer genomicsEkta Khurana, Yao Fu, Vincenza Colonna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trialN W Clarke, A Ali, F C Ingleby, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
Nucleic Acids Research|November 4, 2010
Ensembl 2011Paul Flicek, M Ridwan Amode, Daniel Barrell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
Lancet (London, England)|October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialChristopher C Parker, Nicholas D James, Christopher D Brawley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003N W Clarke, A Ali, F C Ingleby, et al.
Pageof 67